Why is Alivus Life falling/rising?

As of 28-Aug, Alivus Life Sciences Ltd is currently priced at 945.00, reflecting a decrease of 4.45 points or 0.47%. The stock has been underperforming recently, having fallen consecutively for the last two days, resulting in a total decline of 2.51% during this period. Additionally, the stock's performance over the past week shows a decrease of 2.40%, and it has experienced a significant drop of 7.21% over the past month. While the stock has a high management efficiency indicated by a return on equity (ROE) of 25.32% and a low debt-to-equity ratio, it is trading at a premium compared to its peers. The company's net sales growth has been modest at an annual rate of 4.49%, and operating profit growth has been even lower at 2.26% over the last five years, contributing to concerns about its long-term growth potential.
In the broader market context, Alivus Life's recent performance contrasts with the Sensex, which has declined by 2.34% over the same week, indicating that the stock's short-term performance is slightly worse than the benchmark. Despite the stock's recent struggles, it has outperformed its sector by 0.37% today, suggesting some resilience amidst the overall decline. However, the stock's year-to-date performance remains negative at -4.45%, while the Sensex has gained 2.48% in the same timeframe. This disparity highlights the challenges Alivus Life faces in attracting investor confidence, especially given its flat results reported in June and the rising investor participation not translating into positive price movement.